ADC Therapeutics SA SEC filings ADCT
ADC Therapeutics SA has 438 filings in SEC EDGAR's recent list, going back to Jun 27, 2019. Its latest annual report, Form ARS, was filed on Mar 10, 2026 for the period ended Dec 31, 2025. The latest quarterly report (Form 10-Q) was filed on Aug 13, 2026, covering the quarter ended Jun 30, 2026. The most recent current report (Form 8-K) was filed on Nov 4, 2026 (results of operations, regulation fd disclosure, other events). The company's fiscal year ends on December 31.
| Form | Description | Filed | Period |
|---|---|---|---|
| EFFECT | Filing | Mar 16, 2026 | — |
| CORRESP | Letter to the SEC | Mar 12, 2026 | — |
| UPLOAD | Letter from the SEC | Mar 12, 2026 | — |
| EFFECT | Filing | Dec 12, 2025 | — |
| CORRESP | Letter to the SEC | Dec 10, 2025 | — |
| EFFECT | Filing | Jul 9, 2025 | — |
| CORRESP | Letter to the SEC | Jul 7, 2025 | — |
| UPLOAD | Letter from the SEC | Jul 7, 2025 | — |
| EFFECT | Filing | Aug 13, 2024 | — |
| CORRESP | Letter to the SEC | Aug 9, 2024 | — |
| UPLOAD | Letter from the SEC | Aug 9, 2024 | — |
| EFFECT | Filing | Mar 14, 2024 | — |
| EFFECT | Filing | Mar 14, 2024 | — |
| EFFECT | Filing | Mar 14, 2024 | — |
| SC TO-I/A | Form sc to-i/a | Apr 5, 2023 | — |
| SC TO-I/A | Form sc to-i/a | Mar 30, 2023 | — |
| SC TO-I/A | Form sc to-i/a | Mar 29, 2023 | — |
| EFFECT | Filing | Mar 24, 2023 | — |
| CORRESP | Letter to the SEC | Mar 21, 2023 | — |
| UPLOAD | Letter from the SEC | Mar 21, 2023 | — |
| EFFECT | Filing | Mar 20, 2023 | — |
| SC TO-I/A | Form sc 10-1/a | Mar 17, 2023 | — |
| CORRESP | Letter to the SEC | Mar 16, 2023 | — |
| UPLOAD | Letter from the SEC | Mar 14, 2023 | — |
| SC TO-I | Form sc to-i | Mar 6, 2023 | — |
| SC TO-C | Form sc to-c | Mar 3, 2023 | — |
| EFFECT | Filing | Sep 16, 2022 | — |
| EFFECT | Filing | Sep 16, 2022 | — |
| CORRESP | Letter to the SEC | Sep 14, 2022 | — |
| CORRESP | Letter to the SEC | Sep 14, 2022 | — |
| UPLOAD | Letter from the SEC | Sep 13, 2022 | — |
| UPLOAD | Letter from the SEC | Sep 13, 2022 | — |
| POS EX | Filing | Sep 24, 2020 | — |
| EFFECT | Filing | Sep 23, 2020 | — |
| CORRESP | Letter to the SEC | Sep 21, 2020 | — |
| CORRESP | Letter to the SEC | Sep 21, 2020 | — |
| UPLOAD | Letter from the SEC | Sep 14, 2020 | — |
| DRS | Filing | Sep 11, 2020 | — |
| EFFECT | Filing | May 14, 2020 | — |
| CERT | Nyse certification | May 12, 2020 | — |
| CORRESP | Letter to the SEC | May 12, 2020 | — |
| CORRESP | Letter to the SEC | May 12, 2020 | — |
| 8-A12B | Filing | May 11, 2020 | — |
| CORRESP | Letter to the SEC | Apr 28, 2020 | — |
| UPLOAD | Letter from the SEC | Mar 25, 2020 | — |
| DRSLTR | Filing | Mar 2, 2020 | — |
| DRS | Filing | Mar 2, 2020 | — |
| RW | Filing | Oct 3, 2019 | — |
| CORRESP | Letter to the SEC | Oct 3, 2019 | — |
| CERT | Nyse certification filing | Sep 30, 2019 | — |
| 8-A12B | Filing | Sep 30, 2019 | — |
| CORRESP | Letter to the SEC | Sep 30, 2019 | — |
| CORRESP | Letter to the SEC | Sep 30, 2019 | — |
| SEC STAFF LETTER | Filing | Sep 18, 2019 | — |
| CORRESP | Letter to the SEC | Sep 9, 2019 | — |
| DRSLTR | Filing | Aug 14, 2019 | — |
| DRS/A | Filing | Aug 14, 2019 | — |
| UPLOAD | Letter from the SEC | Jul 25, 2019 | — |
| SEC STAFF LETTER | Filing | Jul 18, 2019 | — |
| DRS | Filing | Jun 28, 2019 | — |
| DRSLTR | Filing | Jun 27, 2019 | — |
Showing 61 filings. Main filings leave out insider and ownership forms such as Form 4; choose a type above to see them. Each form opens on SEC.gov. Older filings are on SEC EDGAR.
New to this? Read What Are SEC Filings? 10-K, 10-Q, 8-K and Other Forms Explained.
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- ADCT (NYSE)
- Fiscal year ends
- December 31
- Incorporated in
- Switzerland
- Headquarters
- Epalinges, Switzerland
- SEC filer status
- Non-accelerated filer, Smaller reporting company
- SEC CIK
- 1771910
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Source: SEC EDGAR filings. This is company-reported data, not investment advice.